Dizal (Jiangsu) Pharmaceutical Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Zhang Xiaolin

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	1.8%
Management average tenure	no data
Board average tenure	4yrs

Recent management updates

Recent updates

CEO

Zhang Xiaolin (60 yo)

no data

Tenure

CN¥11,727,700

Compensation

Dr. Zhang Xiaolin Ph.D. is General Manager and Chairman of Dizal (Jiangsu) Pharmaceutical Co., Ltd. and served as its Chief Scientist. Dr. Xiaolin joined the Dizal (Jiangsu) Pharmaceutical Co., Ltd.in 201...

Board Members

Name	Position	Tenure	Compensation	Ownership
Zhang Xiaolin	GM & Chairman	no data	CN¥11.73m	1.76% CN¥ 274.2m
Guanshan Zhu	Independent Director	4yrs	CN¥100.00k	no data
Simon Dazhong Lu	Director	7.7yrs	no data	no data
Rodolphe Peter Andre Grepinet	Director	7.7yrs	no data	no data
Jiang Bin	Independent Director	4yrs	CN¥100.00k	no data
Wang Xuegong	Independent Director	4yrs	CN¥100.00k	no data
Zhang Xin	Independent Director	4yrs	CN¥100.00k	no data
Dong Weiwen	Chairman of the Supervisory Board	no data	no data	no data
Yuan Sun	Supervisor	no data	no data	no data
Xiaojing Kang	Employee Supervisor	2.6yrs	no data	0.0041% CN¥ 637.5k

4.0yrs

Average Tenure

52yo

Average Age

Experienced Board: 688192's board of directors are considered experienced (4 years average tenure).

Dizal (Jiangsu) Pharmaceutical Management

Management criteria checks 1/4

Key information

Recent management updates

Dizal (Jiangsu) Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

Insufficient new directors

Less than half of directors are independent

Recent updates

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Dizal Announces the National Medical Products Administration of China Approves Golidocitinib for the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

New minor risk - Share price stability

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Presents Latest Data from the Inaugural Global Pivotal Study WU-KONG1 Part B (WU-KONG1B) of Sunvozertinib in Relapsed or Refractory Non-Small Cell Lung Cancer

Dizal Reveals New Findings from Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

New major risk - Financial position

Dizal (Jiangsu) Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces Two Abstracts Featuring the Latest Data on Sunvozertinib in Non-Small Cell Lung Cancer

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Dizal's Sunvozertinib for the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

New major risk - Revenue and earnings growth

Now 21% undervalued

Dizal's Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine

Dizal's Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH

New major risk - Share price stability

Dizal Announces Latest Research Findings on the Efficacy and Safety of Sunvozertinib in Treatment-Naive Patients

Insufficient new directors

Dizal Pharmaceutical Receives Priority Review by China NMPA for the Treatment of r/r PTCL

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL

Dizal Pharmaceutical Announces Clinical Results of Golidocitinib Published in Annals of Oncology